Journal
Nature Medicine
Publication Date
12-1-2021
Volume
27
Issue
12
First Page
2192
Last Page
2199
Document Type
Open Access Publication
DOI
10.1038/s41591-021-01539-8
Rights and Permissions
Gotlib, J., Reiter, A., Radia, D.H. et al. Efficacy and safety of avapritinib in advanced systemic mastocytosis: interim analysis of the phase 2 PATHFINDER trial. Nat Med 27, 2192–2199 (2021). doi.org/10.1038/s41591-021-01539-8 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
Recommended Citation
Gotlib, Jason; Reiter, Andreas; Oh, Stephen T; and et al, "Efficacy and safety of avapritinib in advanced systemic mastocytosis: Interim analysis of the phase 2 PATHFINDER trial." Nature Medicine. 27, 12. 2192 - 2199. (2021).
https://digitalcommons.wustl.edu/open_access_pubs/11686
Supplementary Tables 1 and 2
